Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial†
Article first published online: 1 DEC 2013
© 2013 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of The Society for the Study of Addiction
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 109, Issue 3, pages 440–449, March 2014
How to Cite
Konstenius, M., Jayaram-Lindström, N., Guterstam, J., Beck, O., Philips, B. and Franck, J. (2014), Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial. Addiction, 109: 440–449. doi: 10.1111/add.12369
The license for this article was changed to a CC-BY-NC-ND license on 05/02/2014, after initial online publication on 02/12/2013.
- Issue published online: 13 FEB 2014
- Article first published online: 1 DEC 2013
- Accepted manuscript online: 4 OCT 2013 01:45AM EST
- Manuscript Accepted: 25 SEP 2013
- Manuscript Revised: 26 APR 2013
- Manuscript Received: 9 FEB 2013
- Swedish National Board of Health and Welfare
- Swedish Research Council
- Stockholm County Council
Vol. 109, Issue 9, 1571–1572, Article first published online: 8 AUG 2014
- substance use
To test the efficacy and safety of osmotic release oral system (OROS) methylphenidate (MPH) in doses up to 180 mg/day to treat attention deficit hyperactivity disorder (ADHD) and prevent any drug relapse in individuals with a co-diagnosis of ADHD and amphetamine dependence.
Randomized placebo-controlled 24-week double-blind trial with parallel groups design.
Participants were recruited from medium security prisons in Sweden. The medication started within 2 weeks before release from prison and continued in out-patient care with twice-weekly visits, including once-weekly cognitive behavioural therapy.
Fifty-four men with a mean age of 42 years, currently incarcerated, meeting DSM-IV criteria for ADHD and amphetamine dependence.
Change in self-reported ADHD symptoms, relapse to any drug use (amphetamine and other drugs) measured by urine toxicology, retention to treatment, craving and time to relapse.
The MPH-treated group reduced their ADHD symptoms during the trial (P = 0.011) and had a significantly higher proportion of drug-negative urines compared with the placebo group (P = 0.047), including more amphetamine-negative urines (P = 0.019) and better retention to treatment (P = 0.032).
Methylphenidate treatment reduces attention deficit hyperactivity disorder symptoms and the risk for relapse to substance use in criminal offenders with attention deficit hyperactivity disorder and substance dependence.